| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:49 UTC |
|---|
| Update Date | 2022-03-07 02:51:36 UTC |
|---|
| HMDB ID | HMDB0014391 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Ziprasidone |
|---|
| Description | Ziprasidone (marketed as Geodon, Zeldox) was the fifth atypical antipsychotic to gain FDA approval (February 2001). Ziprasidone is Food and Drug Administration (FDA) approved for the treatment of schizophrenia, and the intramuscular injection form of ziprasidone is approved for acute agitation in schizophrenic patients. Ziprasidone has also received approval for acute treatment of mania associated with bipolar disorder. [Wikipedia ] |
|---|
| Structure | ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1 InChI=1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27) |
|---|
| Synonyms | | Value | Source |
|---|
| Ziprasidona | ChEBI | | Ziprasidonum | ChEBI | | Zipradon | Kegg | | Ziprasidone mesylate trihydrate | HMDB | | 5-(2-(4-(3-Benzisothiazolyl)piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one | HMDB | | Ziprasidone hydrochloride | HMDB | | Ziprazidone | HMDB | | Ziprasidone hydrochloride, monohydrate | HMDB | | Geodon | HMDB |
|
|---|
| Chemical Formula | C21H21ClN4OS |
|---|
| Average Molecular Weight | 412.936 |
|---|
| Monoisotopic Molecular Weight | 412.112459711 |
|---|
| IUPAC Name | 5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-2,3-dihydro-1H-indol-2-one |
|---|
| Traditional Name | ziprasidone |
|---|
| CAS Registry Number | 146939-27-7 |
|---|
| SMILES | ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1 |
|---|
| InChI Identifier | InChI=1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27) |
|---|
| InChI Key | MVWVFYHBGMAFLY-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Diazinanes |
|---|
| Sub Class | Piperazines |
|---|
| Direct Parent | N-arylpiperazines |
|---|
| Alternative Parents | |
|---|
| Substituents | - N-arylpiperazine
- 1,2-benzothiazole
- Indole
- Indole or derivatives
- Phenethylamine
- Dialkylarylamine
- N-alkylpiperazine
- Aralkylamine
- Imidolactam
- Benzenoid
- 1,2-thiazolamine
- Aryl chloride
- Aryl halide
- Cyclic carboximidic acid
- Heteroaromatic compound
- Thiazole
- Azole
- Tertiary aliphatic amine
- Tertiary amine
- Organic 1,3-dipolar compound
- Propargyl-type 1,3-dipolar organic compound
- Azacycle
- Amine
- Organohalogen compound
- Organopnictogen compound
- Organic oxygen compound
- Organic nitrogen compound
- Organochloride
- Organonitrogen compound
- Organooxygen compound
- Hydrocarbon derivative
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | > 300 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.0072 g/L | Not Available | | LogP | 3.8 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections| Adduct Type | Data Source | CCS Value (Å2) | Reference |
|---|
| [M+H]+ | CBM | 192.6 | 30932474 |
|
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 4.52 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 10.6543 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 3.15 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 46.2 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1064.1 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 199.8 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 175.9 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 174.1 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 78.7 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 381.6 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 478.9 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 453.4 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 784.1 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 377.2 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1540.2 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 279.3 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 321.0 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 313.8 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 356.9 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 8.8 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Ziprasidone,1TMS,isomer #1 | C[Si](C)(C)N1C(=O)CC2=CC(CCN3CCN(C4=NSC5=CC=CC=C45)CC3)=C(Cl)C=C21 | 3651.1 | Semi standard non polar | 33892256 | | Ziprasidone,1TMS,isomer #1 | C[Si](C)(C)N1C(=O)CC2=CC(CCN3CCN(C4=NSC5=CC=CC=C45)CC3)=C(Cl)C=C21 | 3582.0 | Standard non polar | 33892256 | | Ziprasidone,1TMS,isomer #1 | C[Si](C)(C)N1C(=O)CC2=CC(CCN3CCN(C4=NSC5=CC=CC=C45)CC3)=C(Cl)C=C21 | 4792.9 | Standard polar | 33892256 | | Ziprasidone,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C(=O)CC2=CC(CCN3CCN(C4=NSC5=CC=CC=C45)CC3)=C(Cl)C=C21 | 3820.6 | Semi standard non polar | 33892256 | | Ziprasidone,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C(=O)CC2=CC(CCN3CCN(C4=NSC5=CC=CC=C45)CC3)=C(Cl)C=C21 | 3807.5 | Standard non polar | 33892256 | | Ziprasidone,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C(=O)CC2=CC(CCN3CCN(C4=NSC5=CC=CC=C45)CC3)=C(Cl)C=C21 | 4825.4 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Ziprasidone GC-MS (Non-derivatized) - 70eV, Positive | splash10-00lr-2963000000-73cfc43e5f403e3ecc3c | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Ziprasidone GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Ziprasidone GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Ziprasidone LC-ESI-QFT , positive-QTOF | splash10-01ox-0900400000-0a17dd0e237f50ba91c5 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Ziprasidone 35V, Positive-QTOF | splash10-01ox-0900400000-f48ae3c72fd303348090 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Ziprasidone 40V, Positive-QTOF | splash10-0006-0900000000-af32fe00a14db315cf8b | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Ziprasidone 30V, Positive-QTOF | splash10-0006-0900200000-4a3f1cc15848e67e20a4 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Ziprasidone 10V, Positive-QTOF | splash10-03di-0000900000-a6bfb6420e00cb948710 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Ziprasidone 20V, Positive-QTOF | splash10-03di-0100900000-c6778b116b9686acf160 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Ziprasidone 50V, Positive-QTOF | splash10-05mo-0900000000-7fa49aa5ae170ec5d44d | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Ziprasidone 20V, Positive-QTOF | splash10-03di-0100900000-729ef7c784ed6b441be2 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ziprasidone 10V, Positive-QTOF | splash10-03di-0102900000-fa5da81fd10bba242977 | 2016-08-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ziprasidone 20V, Positive-QTOF | splash10-01po-0977400000-7e1cc88e25385239ddce | 2016-08-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ziprasidone 40V, Positive-QTOF | splash10-01r6-0910000000-cf9cd1eba914ad67bfd4 | 2016-08-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ziprasidone 10V, Negative-QTOF | splash10-03di-0001900000-6744a80d8f97817dd4d9 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ziprasidone 20V, Negative-QTOF | splash10-03xu-1239400000-c4b9e0aa1e6ecda282ad | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ziprasidone 40V, Negative-QTOF | splash10-0006-9771000000-b7a94f6b2c87097c90ab | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ziprasidone 10V, Negative-QTOF | splash10-03di-0000900000-a39ff6e23c7d3ae58642 | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ziprasidone 20V, Negative-QTOF | splash10-01q9-9200700000-1c46f9707ae8ff17a567 | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ziprasidone 40V, Negative-QTOF | splash10-001i-6923100000-63bd8cda1809361ef1d9 | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ziprasidone 10V, Positive-QTOF | splash10-03di-0000900000-eee450689fc3c8c5f739 | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ziprasidone 20V, Positive-QTOF | splash10-03di-0100900000-9282980f21fd87d87ec4 | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ziprasidone 40V, Positive-QTOF | splash10-03di-3925600000-35b0278722002948c536 | 2021-09-25 | Wishart Lab | View Spectrum |
|
|---|